skip to Main Content

Cancer Services

Gastrointestinal Cancer

Please see below all current gastrointestinal cancer clinical trials of the Central Coast Cancer Centre.

Name: PREDICT 5FU

A Study to Describe the Feasibility of Therapeutic Drug Monitoring of 5FU in Cancer Treatment
Principal Investigator: Dr Malmaruha Arasaratnam
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Gastrointestinal Cancer
External page link More information about Predict 5FU study

Name: INTEGRATE II

A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Principal Investigator: Dr Matthew Wong
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Gastrointestinal Cancer
External page link More information about INTEGRATE II

Name: ASCOLT

ASPIRIN FOR DUKES C AND HIGH-RISK DUKES B COLORECTAL CANCERS
An International, Multi‐centre, Double-Blind, Randomised Placebo-Controlled Phase III Trial

Protocol Number: AG0213CR
Principal Investigator: Dr Matthew Wong
Study Coordinator: Richard Clayton
Status: Closed
Condition: Gastrointestinal/Colorectal Cancer
External page link More information about ASCOLT

Name: DYNAMIC III COLON

DYNAMIC III: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer. A Multicentre Phase II/III Randomised Controlled Study.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Colon Cancer
External page link More information about DYNAMIC III

Name: DYNAMIC Rectal

A multicentre randomised study for circulating tumour DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Rectal Cancer
External page link More information about DYNAMIC Rectal

Name: NABNEC

A Randomised Phase II Study Of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Gastric Cancer
External page link More information about NABNEC

Name: Protocol 8951-CL-5201

A phase 2, open-label, randomized study to assess the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as first line treatment in subjects with Claudin 18.2 (CLDN 18.2) positive, metastatic pancreatic adenocarcinoma.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Pancreatic Cancer
External page link More information about Protocol 8951-CL-5201

Name: SGNLV-005

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced metastatic solid tumours.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Closed
Condition: Gastrointestinal Cancer
External page link More information about SGNLV-005

Name: Genescreen 5FU

A Pilot Study of Genotype-guided Personalised Fluoropyrimidine Dosing: Feasibility and Implimentation

Principal Investigator: Dr Craig Kukard
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Gastrointestinal Cancer

Name: MOUNTAINEER-02

A randomised, double-blind, placebo-controlled Phase II/III Study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with gastro eosophageal cancer

Principal Investigator: Dr Matthew Wong
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Gastro-Eosophageal Cancer

External page link More information about MOUNTAINEER- 02

Name: MK 6482

An Open-label, multicentre, phase II study to evaluate the efficacy and safety of pembrolizumab plus lenvatinib in combination with belzutifan in multiple solid tumours.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Carcinoma, Hepatocellular, Colorectal Neoplasms, Biliary Tract Neoplasms, Pancreatic Ductal Ca

External page link More information about MK 6482 hyperlink to

More information

For more information about medical oncology clinical trials, please contact the Nurse Unit Manager on 02 4320 9890 or see:

Internal page Research and Clinical Trials

Back To Top